Folate-mediated drug delivery: effect of alternative conjugation chemistry.
When utilized as a macromolecular drug targeting ligand, folic acid (Pte-Glu) has traditionally been coupled to peptides, proteins and lipids via one of its two carboxylate groups fortuitously located within a distal glutamyl moiety. It has been assumed in the literature that the gamma-glutamyl carboxylate of Pte-Glu is the preferred conjugation site for macromolecules enduring endocytosis via the folate-binding protein receptor. However, it is also possible that the steric placement of the attached macromolecule around the vitamin's pteridine moiety may be the more influential parameter controlling this delivery mechanism. Using solid-phase chemistries, we have synthesized dipeptide derivatives of pteroic acid for the purpose of identifying the preferred site onto which a macromolecule can be chemically attached without compromising its endocytosis potential. Thus, using fluorescent and radiolabeled conjugates, we have determined that macromolecules attached to Pte-Glu by either an alpha- or gamma-glutamyl linkage could associate with receptor-bearing cells at virtually identical levels. We further discovered that removal of the remaining un-conjugated glutamyl carboxylate had no inhibitory effect on cell uptake; and, the cytotoxicity of related momordin toxin conjugates were comparable among the various pteroate derivatives tested. From these observations we suggest that the preparation of endocytosis-competent pteroate-macromolecule conjugates is strongly influenced by the steric environment around the ligand's para-aminobenzoic acid moiety, and that no selective isomeric (i.e. alphaGlu versus gammaGlu) conjugation requirement necessarily exists.
Leamon
C P
CP
Department of Oligomer Development, GlaxoWellcome Research Institute, Research Triangle Park, NC 27709, USA. Leamon@Endocyte.com
DePrince
R B
RB
Hendren
R W
RW
D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000633:toxicity; D002470:Cell Survival / Q000187:drug effects; D004151:Dipeptides / Q000138:chemical synthesis / Q000494:pharmacology; D004705:Endocytosis / Q000187:drug effects; D005492:Folic Acid / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006367:HeLa Cells; D006397:Hematinics / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007553:Isotope Labeling; D018613:Microscopy, Confocal; D009699:N-Glycosyl Hydrolases; D010455:Peptides / Q000737:chemistry; D010940:Plant Proteins / Q000737:chemistry / Q000633:toxicity; D011485:Protein Binding; D011622:Pterins / Q000737:chemistry; D054790:Ribosome Inactivating Proteins, Type 2; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship
D000964:Antimetabolites, Antineoplastic; D004151:Dipeptides; D006397:Hematinics; D010455:Peptides; D010940:Plant Proteins; D011622:Pterins; D054790:Ribosome Inactivating Proteins, Type 2; C005584:pteroic acid; D005492:Folic Acid; D009699:N-Glycosyl Hydrolases